Browsing Nuclear Medicine by Subject "177Lu-PSMA"

Now showing items 1-2 of 2

213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer

Sathekge, Mike Machaba; Knoesen, Otto; Meckel, Marian; Modiselle, Moshe; Vorster, Mariza; Marx, Sebastian (Springer, 2017-06)

Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA holds great promise as a safe treatment option in patients with metastasized castration-resistant prostate cancer (mCRPC) with ...
South African guidelines for receptor radioligand therapy (RLT) with Lu-177-PSMA in prostate cancer

Vorster, Mariza; Warwick, J.; Lawal, Ismaheel Opeyemi; Du Toit, P.; Vangu, M.; Nyakale, N.E.; Steyn, R.; Gutta, A.A.; Hart, G.; Mutambirwa, S.; Ellmann, A.; Sathekge, Mike Machaba (South African Medical Association, 2019-12)

BACKGROUND : Prostate cancer is an important cause of morbidity and mortality in South Africa, as it is in the rest of the world. In African men, however, prostate cancer tends to follow a more aggressive course when ...

Now showing items 1-2 of 2

Search UPSpace